Rapid Detection of Mycobacterium tuberculosis and Rifampin Resistance by Use of On-Demand, Near-Patient Technology
Open accessThe DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Abstract
Current nucleic acid amplification methods to detect Mycobacterium tuberculosis are complex, labor-intensive, and technically challenging. We developed and performed the first analysis of the Cepheid Gene Xpert System's MTB/RIF assay, an integrated hands-free sputum-processing and real-time PCR system with rapid on-demand, near-patient technology, to simultaneously detect M. tuberculosis and rifampin resistance. Analytic tests of M. tuberculosis DNA demonstrated a limit of detection (LOD) of 4.5 genomes per reaction. Studies using sputum spiked with known numbers of M. tuberculosis CFU predicted a clinical LOD of 131 CFU/ml. Killing studies showed that the assay's buffer decreased M. tuberculosis viability by at least 8 logs, substantially reducing biohazards. Tests of 23 different commonly occurring rifampin resistance mutations demonstrated that all 23 (100%) would be identified as rifampin resistant. An analysis of 20 nontuberculosis mycobacteria species confirmed high assay specificity. A small clinical validation study of 107 clinical sputum samples from suspected tuberculosis cases in Vietnam detected 29/29 (100%) smear-positive culture-positive cases and 33/39 (84.6%) or 38/53 (71.7%) smear-negative culture-positive cases, as determined by growth on solid medium or on both solid and liquid media, respectively. M. tuberculosis was not detected in 25/25 (100%) of the culture-negative samples. A study of 64 smear-positive culture-positive sputa from retreatment tuberculosis cases in Uganda detected 63/64 (98.4%) culture-positive cases and 9/9 (100%) cases of rifampin resistance. Rifampin resistance was excluded in 54/55 (98.2%) susceptible cases. Specificity rose to 100% after correcting for a conventional susceptibility test error. In conclusion, this highly sensitive and simple-to-use system can detect M. tuberculosis directly from sputum in less than 2 h.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies have shown that Xpert does not cross‐react with other mycobacterial species (Blakemore 2010; Helb 2010).”
From Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults (2021) · cites this paper as Helb 2010
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This represents a substantial reduction in diagnostic delay, thereby permitting real-time decision making and planning of treatment (5).”
From Xpert MTB/RIF for Rapid Diagnosis of Tuberculous Lymphadenitis from Fine-Needle-Aspiration Biopsy Specimens (2011) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“Previous studies reported 98–100% agreement in detection of rifampicin resistance strains using the Xpert test and phenotypic drug susceptibility test [13,14,18,26].”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“Such cases (Xpert-positive but culture-negative) are likely to be true TB positives as corroborated by the high specificity [14,18] and by the fact that the procedure is less prone to contamination due to the closed reaction chamber (real-time PCR technology) of Xpert.”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“In agreement with other studies [9,18,22], Xpert has a higher sensitivity than smear microscopy.”
From GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings (2015) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A., Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G., Iademarco, M. F., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-571st · Cited by 6,110
Two-sided confidence intervals for the single proportion: comparison of seven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e · Cited by 5,107
Probable Inference, the Law of Succession, and Statistical Inference
Wilson, E. B. (1927) · Journal of the American Statistical Association · doi:10.1080/01621459.1927.10502953 · Cited by 4,476
Sexually transmitted diseases treatment guidelines
Burstein, G. R., & Workowski, K. A. (2003) · Current Opinion in Pediatrics · doi:10.1097/00008480-200308000-00006 · Cited by 2,072
Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines
Workowski, K. A., & Berman, S. M. (2007) · Clinical Infectious Diseases · doi:10.1086/511430 · Cited by 1,973
The association for the advancement of medical instrumentation
(1974) · Ultrasound in Medicine & Biology · doi:10.1016/0301-5629(74)90035-0 · Cited by 1,031
Anti-tuberculosis drug resistance in the world
Wilkinson, D. (1998) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(98)90766-0 · Cited by 700
Molecular Detection of Antimicrobial Resistance
Fluit, A. C., Visser, M. R., & Schmitz, F.-J. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.836-871.2001 · Cited by 525 · cited 1×
“tuberculosis detection (15), this assay was too complex and too prone to operator errors, sample cross-contamination, and biohazards for rapid near-patient use.”
BackgroundEspinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507 · cited 3×
“Truly rapid results for drug susceptibility tests are particularly important in the management of drug-resistant tuberculosis (13).”
BackgroundMicroscopic-Observation Drug-Susceptibility Assay for the Diagnosis of TB
Moore, D. A. J., Evans, C. A. W., Gilman, R. H., Caviedes, L., Coronel, J., Vivar, A., Sanchez, E., Piñedo, Y., Saravia, J. C., Salazar, C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055524 · Cited by 468
Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis
Piatek, A. S., Tyagi, S., Pol, A. C., Telenti, A., Miller, L. P., Kramer, F. R., & Alland, D. (1998) · Nature Biotechnology · doi:10.1038/nbt0498-359 · Cited by 419
Self-citationComprehensive Treatment of Extensively Drug-Resistant Tuberculosis
Mitnick, C. D., Shin, S. S., Seung, K. J., Rich, M. L., Atwood, S. S., Furin, J. J., Fitzmaurice, G. M., Alcantara Viru, F. A., Appleton, S. C., Bayona, J. N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800106 · Cited by 402
Barnard, M., Albert, H., Coetzee, G., O'Brien, R., & Bosman, M. E. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1436oc · Cited by 391 · cited 2×
“Such errors have been reported in other studies (2) and is especially likely in this case since this isolate was known to be resistant to both isoniazid and ethambutol.”
BackgroundResultGlobal Tuberculosis Programme, & Disease, L. (1997) · Medical Entomology and Zoology · Cited by 361
Hillemann, D., Rüsch-Gerdes, S., & Richter, E. (2007) · Journal of Clinical Microbiology · doi:10.1128/jcm.00521-07 · Cited by 345 · cited 1×
“Currently available methods fall short of this promise (4, 9, 10, 19, 23, 30, 38, 40).”
MethodKapur, V, Li, L. L., Iordanescu, S., Hamrick, M. R., Wanger, A., Kreiswirth, B. N., & Musser, J. M. (1994) · Journal of Clinical Microbiology · doi:10.1128/jcm.32.4.1095-1098.1994 · Cited by 317 · cited 1×
“tuberculosis genomic DNA from drug-susceptible and rifampin-resistant clinical isolates, including isolates with 12 of the 19 most commonly described RRDR mutations (5, 7, 21, 22, 25, 26, 28, 31, 33, 46, 54).”
BackgroundMulticenter Evaluation of the BACTEC MGIT 960 System for Recovery of Mycobacteria
Hanna, B. A., Ebrahimzadeh, A., Elliott, L. B., Morgan, M. A., Novak, S. M., Rusch-Gerdes, S., Acio, M., Dunbar, D. F., Holmes, T. M., Rexer, C. H., et al. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.3.748-752.1999 · Cited by 292 · cited 2×
“Currently available methods fall short of this promise (4, 9, 10, 19, 23, 30, 38, 40).”
BackgroundMethodCruciani, M., Scarparo, C., Malena, M., Bosco, O., Serpelloni, G., & Mengoli, C. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.5.2321-2325.2004 · Cited by 291 · cited 1×
“on Lowenstein-Jensen medium (32), and Bactec MGIT 960 liquid culture (8).”
BackgroundCaviedes, L., Lee, T.-S., Gilman, R. H., Sheen, P., Spellman, E., Lee, E. H., Berg, D. E., Montenegro-James, S., & The Tuberculosis Working Group in Peru (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.3.1203-1208.2000 · Cited by 277
Heep, M., Brandstätter, B., Rieger, U., Lehn, N., Richter, E., Rüsch-Gerdes, S., & Niemann, S. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.1.107-110.2001 · Cited by 240 · cited 1×
“tuberculosis genomic DNA from drug-susceptible and rifampin-resistant clinical isolates, including isolates with 12 of the 19 most commonly described RRDR mutations (5, 7, 21, 22, 25, 26, 28, 31, 33, 46, 54).”
BackgroundRossau, R., Traore, H., De Beenhouwer, H., Mijs, W., Jannes, G., De Rijk, P., & Portaels, F. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2093 · Cited by 231 · cited 2×
“A number of new diagnostic approaches have brought incremental improvements in detection and drug susceptibility testing (2, 9, 19, 24, 37, 41, 46); however, none can realistically provide actionable information within the time frame of a single office or clinic visit.”
BackgroundPiatek, A. S., Telenti, A., Murray, M. R., El-Hajj, H., Jacobs, W. R., Kramer, F. R., & Alland, D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.1.103-110.2000 · Cited by 218 · cited 2×
“tuberculosis from New York City, Madrid (42), India, and Mexico (51).”
BackgroundSelf-citationHillemann, D., Weizenegger, M., Kubica, T., Richter, E., & Niemann, S. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.8.3699-3703.2005 · Cited by 209 · cited 1×
“A number of new diagnostic approaches have brought incremental improvements in detection and drug susceptibility testing (2, 9, 19, 24, 37, 41, 46); however, none can realistically provide actionable information within the time frame of a single office or clinic visit.”
BackgroundSexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention.
(2002) · PubMed · Cited by 185
El-Hajj, H. H., Marras, S. A. E., Tyagi, S., Kramer, F. R., & Alland, D. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.11.4131-4137.2001 · Cited by 180 · cited 2×
“9) 54 (84) 2–3 0 7 (11) 4–5 0 3 (5) Median duration of cough (days range 28 (14–336) 90 (21–365)”
MethodSelf-citationMusial, C. E., Tice, L. S., Stockman, L., & Roberts, G. D. (1988) · Journal of Clinical Microbiology · doi:10.1128/jcm.26.10.2120-2123.1988 · Cited by 169 · cited 1×
“Currently available methods fall short of this promise (4, 9, 10, 19, 23, 30, 38, 40).”
MethodD'Amato, R. F., Wallman, A. A., Hochstein, L. H., Colaninno, P. M., Scardamaglia, M., Ardila, E., Ghouri, M., Kim, K., Patel, R. C., & Miller, A. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.7.1832-1834.1995 · Cited by 158 · cited 2×
“Currently available methods fall short of this promise (4, 9, 10, 19, 23, 30, 38, 40).”
BackgroundMethodTraore, H., Fissette, K., Bastian, I., Devleeschouwer, M. J., & Portaels, F. (2000) · PubMed · Cited by 152
The dilemma of MDR-TB in the global era.
Farmer, P. E., Bayona, J. N., Becerra, M. C., Furin, J. J., Henry, C., Hiatt, H. H., Kim, J. Y., Mitnick, C. D., Nardell, E. A., & Shin, S. S. (1998) · PubMed · Cited by 151
Yang, B., Koga, H., Ohno, H., Ogawa, K., Fukuda, M., Hirakata, Y., Maesaki, S., Tomono, K., Tashiro, T., & Kohno, S. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.5.621 · Cited by 148 · cited 1×
“tuberculosis genomic DNA from drug-susceptible and rifampin-resistant clinical isolates, including isolates with 12 of the 19 most commonly described RRDR mutations (5, 7, 21, 22, 25, 26, 28, 31, 33, 46, 54).”
BackgroundTechnology for Automated, Rapid, and Quantitative PCR or Reverse Transcription-PCR Clinical Testing
Raja, S., Ching, J., Xi, L., Hughes, S. J., Chang, R., Wong, W., McMillan, W., Gooding, W. E., McCarty, K. S., Chestney, M., et al. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.046474 · Cited by 136 · cited 2×
“The Cepheid GeneXpert System (Sunnyvale, CA), a singleuse sample-processing cartridge system with integrated multicolor real-time PCR capacity (45), has the potential to greatly simplify nucleic acid amplification tests.”
MethodCaws, M., Phan, M., Tho, D. Q., Lan, N. T. N., Hoa, D. V., & Farrar, J. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.00330-06 · Cited by 122 · cited 3×
“9) 54 (84) 2–3 0 7 (11) 4–5 0 3 (5) Median duration of cough (days range 28 (14–336) 90 (21–365)”
BackgroundSelf-citationChan, R. C. Y., Hui, M., Chan, E. W., Au, T. K., Chin, M. L., Yip, C. K., Au-Yeang, C., Yeung, C. Y. L., Kam, K. M., Yip, P. C. W., et al. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm054 · Cited by 117
Lipin, M. Y., Stepanshina, V. N., Shemyakin, I. G., & Shinnick, T. M. (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2007.01711.x · Cited by 109 · cited 1×
“tuberculosis genomic DNA from drug-susceptible and rifampin-resistant clinical isolates, including isolates with 12 of the 19 most commonly described RRDR mutations (5, 7, 21, 22, 25, 26, 28, 31, 33, 46, 54).”
BackgroundGavino, M., & Wang, E. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.06.016 · Cited by 102 · cited 2×
“% ) Normal 0 7 (12) Minimal 21 (26) 2 (4) Moderate 34 (41) 9 (16) Severe 27 (33) 38 (68)”
MethodВладиславович, М. И., Otten, T., Vyshnevskiy, B. I., & Narvskaya, O. V. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2231-2235.2003 · Cited by 92
Herrera, L., Jiménez, S., Valverde, A., García-Aranda, M. A., & Sáez-Nieto, J. A. (2003) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(03)00036-0 · Cited by 90 · cited 1×
“tuberculosis genomic DNA from drug-susceptible and rifampin-resistant clinical isolates, including isolates with 12 of the 19 most commonly described RRDR mutations (5, 7, 21, 22, 25, 26, 28, 31, 33, 46, 54).”
BackgroundEing, B. R., Becker, A., Sohns, A., & Ringelmann, R. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.7.2023-2029.1998 · Cited by 90 · cited 2×
“Currently available methods fall short of this promise (4, 9, 10, 19, 23, 30, 38, 40).”
MethodHasegawa, N., Miura, T., Ishii, K., Yamaguchi, K., Lindner, T. H., Merritt, S., Matthews, J. D., & Siddiqi, S. H. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.3.908-912.2002 · Cited by 88 · cited 1×
“tuberculosis by MPT64 antigen detection using the Capilia TB test (20).”
MethodHuitric, E., Werngren, J., Juréen, P., & Hoffner, S. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00303-06 · Cited by 77 · cited 2×
“% ) Normal 0 7 (12) Minimal 21 (26) 2 (4) Moderate 34 (41) 9 (16) Severe 27 (33) 38 (68)”
BackgroundTemple, B., Ayakaka, I., Ogwang, S., Nabanjja, H., Kayes, S., Nakubulwa, S. K., Worodria, W. O., Levin, J. B., Joloba, M. L., Okwera, A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/592252 · Cited by 77 · cited 1×
“This patient group was studied because retreatment tuberculosis cases have higher rates of drug resistance than initial tuberculosis cases (48).”
BackgroundSelf-citationPark, W. G., Bishai, W. R., Chaisson, R. E., & Dorman, S. E. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.12.4750-4752.2002 · Cited by 67 · cited 2×
“% ) Normal 0 7 (12) Minimal 21 (26) 2 (4) Moderate 34 (41) 9 (16) Severe 27 (33) 38 (68)”
BackgroundGenotyping SNPs With Molecular Beacons
Marras, S. A. E., Kramer, F. R., & Tyagi, S. (2003) · Single Nucleotide Polymorphisms · doi:10.1385/1-59259-327-5:111 · Cited by 66 · cited 1×
“sent in rifampin-susceptible strains), were detected by five overlapping molecular beacons (34).”
BackgroundPrammananan, T., Cheunoy, W., Taechamahapun, D., Yorsangsukkamol, J., Phunpruch, S., Phdarat, P., Leechawengwong, M., & Chaiprasert, A. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.01951.x · Cited by 58
Evaluation of the Cepheid GeneXpertR system for detecting Bacillus anthracis
Ulrich, M. P., Christensen, D. R., Coyne, S. R., Craw, P. D., Henchal, E. A., Sakai, S. H., Swenson, D., Tholath, J., Tsai, J.-L., Weir, A. F., et al. (2006) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.2006.02810.x · Cited by 57 · cited 1×
“Importantly, the assay makes use of a basic cartridge design and an instrument platform that are currently used in commercially available assays for rapid detection of methicillin-resistant Staphylococcus aureus, enteroviruses, Bacillus anthracis (50), and group B Streptococcus (16) and that is also likely to be used…”
MethodLemaître, N., Armand, S., Vachée, A., Capilliez, O., Dumoulin, C., & Courcol, R. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.9.4307-4309.2004 · Cited by 57 · cited 1×
“Currently available methods fall short of this promise (4, 9, 10, 19, 23, 30, 38, 40).”
MethodBasil, M. V., El-Hajj, H. H., Colangeli, R., Hazbón, M. H., Kumar, S., Bose, M., Bobadilla-del-Valle, M., García‐García, L., Hernández, A., Kramer, F. R., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.12.5512-5516.2004 · Cited by 46 · cited 2×
“tuberculosis from New York City, Madrid (42), India, and Mexico (51).”
BackgroundSelf-citationHuang, H., Jin, Q., Ma, Y., Chen, X., & Zhuang, Y. (2002) · Tuberculosis · doi:10.1054/tube.2002.0326 · Cited by 46
Mani, C., Selvakumar, N., Kumar, V., Narayanan, S., & Narayanan, P. R. (2003) · PubMed · Cited by 39
Tanoue, L. T. (2008) · Yearbook of Pulmonary Disease · doi:10.1016/s8756-3452(08)70748-5 · Cited by 37
Feasibility of Shortening Respiratory Isolation with a Single Sputum Nucleic Acid Amplification Test
Campos, M., Quartin, A. A., Mendes, E. S., Abreu, A. R., Gurevich, S., Echarte, L., Ferreira, T., Cleary, T., Hollender, E. S., & Ashkin, D. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200803-381oc · Cited by 36 · cited 3×
“% ) 7 5 (6) 54 (84) 7–21 73 (89) 8 (13) 21 4 (5) 2 (3)”
BackgroundHunt, J. M., Roberts, G. D., Stockman, L., Felmlee, T. A., & Persing, D. H. (1994) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(94)90024-8 · Cited by 35 · cited 1×
“tuberculosis and rifampin resistance could be accomplished simultaneously (27); more recently, our group developed a single-tube, molecular beacon-based real-time PCR assay for the detection of rifampin-resistant M.”
BackgroundSelf-citationEnglund, S., Bölske, G., Ballagi‐Pordány, A., & Johansson, K. (2001) · Veterinary Microbiology · doi:10.1016/s0378-1135(01)00348-0 · Cited by 34 · cited 3×
“% ) Normal 0 7 (12) Minimal 21 (26) 2 (4) Moderate 34 (41) 9 (16) Severe 27 (33) 38 (68)”
MethodDraft Guideline for Disinfection and Sterilization in Healthcare Facilities
Rutala, W. A., & Weber, D. J. (2002) · Cited by 29
Limits of commercial molecular tests for diagnosis of pulmonary tuberculosis
Lebrun, L., Mathieu, D., Saulnier, C., & Nordmann, P. (1997) · European Respiratory Journal · doi:10.1183/09031936.97.10081874 · Cited by 28 · cited 1×
“Thus, the limit of detection of the Xpert MTB/ RIF assay in sputum appeared to be close to that of culture and at least 2 orders of magnitude more sensitive than the AFB smear (29).”
BackgroundComparison of Three Culture Media for Isolation of Mycobacterium tuberculosis : a 6-Year Study
Liu, P. I., McGregor, D. H., FAUCHER, I. O., Jinks, W. L., Miller, L. A., Green, L., & Liu, J. G. (1973) · Applied Microbiology · doi:10.1128/am.26.6.880-883.1973 · Cited by 22
Gebre-Selassie, S. (2003) · Tropical Doctor · doi:10.1177/004947550303300313 · Cited by 17 · cited 1×
“trated quantitative acid-fast bacillus (AFB) microscopy (17), quantitative culture”
MethodÖzkütük, A., Kırdar, S., Özden, S., & Esen, N. (2006) · PubMed · Cited by 14
Cited by
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309
Self-citationXpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults
Steingart, K. R., Schiller, I., Horne, D. J., Pai, M., Boehme, C. C., & Dendukuri, N. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009593.pub3 · Cited by 1,102
Self-citationBoehme, C. C., Nicol, M. P., Nabeta, P., Michael, J. S., Gotuzzo, E., Tahirli, R., Gler, M. T., Blakemore, R., Worodria, W., Gray, C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60438-8 · Cited by 1,013
Self-citationLewinsohn, D. M., Leonard, M. K., LoBue, P. A., Cohn, D. L., Daley, C. L., Desmond, E., Keane, J., Lewinsohn, D. A., Loeffler, A. M., Mazurek, G. H., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw694 · Cited by 992
“These assays are promising, but are not yet commercially available [146, 159, 160].”
BackgroundTuberculous meningitis: a uniform case definition for use in clinical research
Marais, S., Thwaites, G., Schoeman, J. F., Török, M. E., Misra, U. K., Prasad, K., Donald, P. R., Wilkinson, R. J., & Marais, B. J. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70138-9 · Cited by 932
Metadata
- Authors
- Helb, D., Jones, M., Story, E., Boehme, C., Wallace, E., Ho, K., Kop, J., Owens, M. R., Rodgers, R., Banada, P., Safi, H., Blakemore, R., Lan, N. T. N., Jones-López, E. C., Levi, M., Burday, M., Ayakaka, I., Mugerwa, R. D., McMillan, B., Winn-Deen, E., Christel, L., Dailey, P., Perkins, M. D., Persing, D. H., & Alland, D.
- Affiliations
- Rutgers New Jersey Medical School (US)
- Cepheid (United States) (US)
- Department of Medicine, New Jersey Medical School, University of Medicine and Dentistry, New Jersey, Newark, New Jersey
- FIND (CH)
- Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam
- Montefiore Medical Center (US)
- Makerere University (UG)
- ORCID
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2010-01
- Volume
- 48
- Issue
- 1
- Pages
- 229-237
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- PMC
- PMC2812290
- OpenAlex
- W2112022845
- Cited by
- 914
- References
- 59
- Citations by year
- 2026: 29 · 2025: 38 · 2024: 35 · 2023: 33 · 2022: 36 · 2021: 45 · 2020: 65 · 2019: 55 · 2018: 61 · 2017: 62 · 2016: 63 · 2015: 62 · 2014: 74 · 2013: 71 · 2012: 62
- FWCI
- 41.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Rutgers University Community Repository (Rutgers University) (submittedVersion)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (R41AI052523, R42AI052523, R42-AI52523, R41-AI52523)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Keywords
- Mycobacterium tuberculosis detection, rifampicin resistance, Xpert MTB/RIF, point-of-care testing, real-time PCR, sputum, detection limit, nontuberculous mycobacteria, retreatment tuberculosis, tuberculosis diagnosis
- MeSH terms
- Adolescent, Adult, Aged, Antitubercular Agents, Bacteriological Techniques, Female, Humans, Male, Middle Aged, Mycobacterium tuberculosis, Rifampin, Sensitivity and Specificity, Sputum, Tuberculosis, Uganda, Vietnam, Polymerase Chain Reaction, Point-of-Care Systems, Drug Resistance, Bacterial, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.